Jefferies Group began coverage on shares of TherapeuticsMD Inc (NASDAQ:TXMD) in a research note published on Tuesday morning. The brokerage issued a buy rating and a $18.00 target price on the stock.

Separately, Oppenheimer Holdings Inc. started coverage on TherapeuticsMD in a research note on Tuesday. They issued an outperform rating and a $12.00 price target for the company.

TherapeuticsMD (NASDAQ:TXMD) traded down 0.41% on Tuesday, hitting $7.28. The stock had a trading volume of 610,970 shares. TherapeuticsMD has a 12 month low of $4.39 and a 12 month high of $11.26. The company’s 50 day moving average is $6.26 and its 200-day moving average is $7.34. The stock’s market cap is $1.43 billion.

Large investors have recently added to or reduced their stakes in the stock. Sanders Morris Harris Inc. boosted its stake in TherapeuticsMD by 18.9% in the third quarter. Sanders Morris Harris Inc. now owns 506,100 shares of the company’s stock worth $3,446,000 after buying an additional 80,500 shares during the period. State of Wisconsin Investment Board acquired a new stake in TherapeuticsMD during the third quarter worth approximately $2,724,000. First Trust Advisors LP boosted its stake in TherapeuticsMD by 74.5% in the third quarter. First Trust Advisors LP now owns 90,707 shares of the company’s stock worth $618,000 after buying an additional 38,723 shares during the period. Aperio Group LLC acquired a new stake in TherapeuticsMD during the third quarter worth approximately $164,000. Finally, TD Asset Management Inc. boosted its stake in TherapeuticsMD by 3.5% in the third quarter. TD Asset Management Inc. now owns 551,300 shares of the company’s stock worth $3,754,000 after buying an additional 18,400 shares during the period.

TRADEMARK VIOLATION NOTICE: “TherapeuticsMD Inc (TXMD) Receives New Coverage from Analysts at Jefferies Group” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/23/therapeuticsmd-inc-txmd-receives-new-coverage-from-analysts-at-jefferies-group.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.